Whalesbook
SMS Pharmaceuticals' shares rallied significantly following the US FDA's approval of reformulated Ranitidine tablets from its associate, VKT Pharma, marking the drug's return to the US market. The company also reported a record quarterly profit after tax (PAT) of ₹25.32 crore, an 80% year-on-year increase, driven by strong revenue growth and margin expansion. The positive outlook for FY26 further fuels investor interest.